Tests semaglutide in adults with type 1 diabetes and excess weight
Tests semaglutide, compared with a placebo, in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Semaglutide Treatment in Type 1 Diabetes
Key facts
- Where
- Aarhus N, Esbjerg, Herlev, Hilleroed, and Koege, DenmarkSee the 5 sites
- Phase
- Phase 3
Where in Denmark
- Aarhus UniversitetAarhus N, DenmarkTaking people
- Esbjerg Og Grindsted SygehusEsbjerg, DenmarkTaking people
- Steno Diabetes Center CopenhagenHerlev, DenmarkTaking people
- Region HovedstadenHilleroed, DenmarkTaking people
- Region SjaellandKoege, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nordsjaellands Hospital
- Trial code
- NCT06909006EU 2025-522326-13-00
- Record updated
- 8 August 2025
- Original description
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.Read full original descriptionShow less
Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Inclusion: Type 1 Diabetes for more than 3 years; BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis.
Exclusion: Treated with GLP1-RAs within last 6 months; Alcohol/drug abuse; Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation; Receipt of an investigational drug within 30 days prior to visit 0 / Simultaneous participation in any other clinical intervention trial; Other forms of diabetes; History of thyroid adenoma or carcinoma; Liver disease with elevated plasma alanine aminotransferase (ALT) > five times and plasma aspartate aminotransferase (AST) > five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive); Cancer, unless in complete remission for > 5 years or unless basocellular carcinomas; Known intolerance for semaglutide; Pregnant or nursing women; Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives; Acute or chronic pancreatitis.